Antitumor and antiangiogenic activity of cediranib in a preclinical model of renal cell carcinoma. by Medinger, M, Esser, N, Zirrgiebel, U, Ryan, A, Jürgensmeier, J, Drevs, J

Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. by Morelli, M, Brown, A, Pitts, T, Tentler, J, Ciardiello, F, Ryan, A, Jürgensmeier, J, Eckhardt, S

Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. by Smith, N, Baker, D, James, N, Ratcliffe, K, Jenkins, M, Ashton, SE, Sproat, G, Swann, R, Gray, N, Ryan, A, Jürgensmeier, J, Womack, C

MEK1/2 blockade by AZD6244 (ARRY-142886) inhibits tumor growth and progression in an orthotopic human lung adenocarcinoma model with enhanced efficacy when combined with cediranib by Takahashi, O, Komaki, R, Smith, P, Ryan, A, Jurgensmeier, J, Welsh, J, Jacoby, J, Hosho, K, Korshunova, M, Erez, B, Herbst, R, O'Reilly, MS

Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. by Takahashi, O, Komaki, R, Smith, P, Jürgensmeier, J, Ryan, A, Bekele, B, Wistuba, I, Jacoby, J, Korshunova, M, Biernacka, A, Erez, B, Hosho, K, Herbst, R, O'Reilly, MS

Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis by Takahashi, O, Komaki, R, Smith, P, Jürgensmeier, J, Ryan, A, Bekele, B, Wistuba, I, Jacoby, J, Korshunova, M, Biernacka, A, Erez, B, Hosho, K, Herbst, R, O'Reilly, MS